Skip to main content

General Toxicology, Safety Pharmacology, Reproductive Toxicology, and Juvenile Toxicology Studies

  • Chapter
Nonclinical Statistics for Pharmaceutical and Biotechnology Industries

Part of the book series: Statistics for Biology and Health ((SBH))

  • 3074 Accesses

Abstract

This chapter provides a survey of key nonclinical safety assays. For each study type, we discuss the typical study designs employed, including a summary of the type of endpoints collected. We then provide an overview of common statistical approaches in each setting. There are some general themes that are common across the study types (e.g., trend testing). At the same time, the different study types may have features that require special consideration (e.g., cross-over designs for safety pharmacology studies, intra-litter correlation in reproductive toxicology studies). While some of the design aspects of these studies are to some extent “fixed” by precedent across the industry, we do address sample size and power considerations, as this information can be valuable to understanding how statistical results can contribute to the overall interpretation of these studies. Finally, for any discussion of statistical approaches, there are likely to be multiple reasonable approaches. We’ve attempted to cover some of the more common approaches in detail, but we recognize that our treatment is not exhaustive. Where possible, we have provided references for further reading.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bailey SA (1998) Subchronic toxicity studies. In: Chow S-C, Liu J-P (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 135–195

    Google Scholar 

  • Bailey S (2006) Design and analysis issues in juvenile animal toxicity studies for pharmaceutical development: a statistician’s perspective. Poster presented at the teratology society meetings, Tucson, AZ, 26 June 2006. Abstract: Birth Defects Research 76, p 383

    Google Scholar 

  • Bailey S (2008) Relationships between litter size and resorptions, dead, and live fetuses: implications for statistical analysis and data interpretation. Poster presented at the teratology society meetings, Monterey, CA, 30 June 2008. Abstract: Birth Defects Research 82, p 352

    Google Scholar 

  • Barlow RE, Bartholomew DJ, Bremner JM, Brunk HD (1972) Statistical inference under order restrictions. Wiley, New York

    MATH  Google Scholar 

  • Bradley DR, Russell RL (1998) Some cautions regarding statistical power in split-plot designs. Behav Res Methods Insturm Comput 30(3):462–477

    Google Scholar 

  • Bretz F, Hothorn LA (2003) Statistical analysis of monotone or non-monotone dose–response data from in vitro toxicological assays. Altern Lab Anim 31:81–96

    Google Scholar 

  • Catalano PJ, Ryan LM (1992) Bivariate latent variable models for clustered discrete and continuous outcomes. J Am Stat Assoc 87:651–658

    Article  Google Scholar 

  • Catalano PJ, Scharfstein DO, Ryan LM, Kimmel CA, Kimmel GL (1993) Statistical model for fetal death, fetal weight, and malformation in developmental toxicity studies. Teratology 47: 281–290

    Article  Google Scholar 

  • Chen J (1998) Analysis of reproductive and developmental studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 309–355

    Google Scholar 

  • Chen J (2000) Reproductive studies. In: Chow S (ed) Encyclopedia of biopharmaceutical statistics. Marcel Dekker, New York, pp 445–453

    Google Scholar 

  • Chen J, Gaylor D (1992) Correlations of developmental end points observed after 2,4,5-trichlorophenoxyacetic acid exposure in mice. Teratology 45:241–246

    Article  Google Scholar 

  • Chen JJ, Kodell RL, Howe RB, Gaylor DW (1991) Analysis of trinomial responses from reproductive and developmental toxicity experiments. Biometrics 47:1049–1058

    Article  Google Scholar 

  • Ciminera J (1985) Some issues in the design, evaluation, and interpretation of tumorigenicity studies in animals. In: Proceedings of the symposium on long-term animal carcinogenicity studies: a statistical perspective. American Statistical Association, Washington, DC, pp 26–35

    Google Scholar 

  • Clinical and Laboratory Standards Institute (2000) How to define and determine reference intervals in the clinical laboratory: approved guideline, vol 2. CLSI, CLSI document C28-A2, Wayne

    Google Scholar 

  • Crump K (1984) A new method for determining allowable daily intakes. Fundam Appl Toxicol 4:854–871

    Article  Google Scholar 

  • Dorato MA, Engelhardt JA (2005) The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxcol Pharmacol 42:265–274

    Article  Google Scholar 

  • Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096–1121

    Article  MATH  Google Scholar 

  • EP Evaluator (2005) Release 7 (EE7). Computer software for evaluating clinical laboratory methods. David G. Rhoads Associates, Kennett Square

    Google Scholar 

  • Filipsson AF, Sand S, Nilsson J, Victorin K (2003) The benchmark dose method—review of available models, and recommendations for application in health risk assessment. Crit Rev Toxicol 33(5):505–542

    Google Scholar 

  • Healey GF (1999) The F1 approximate parametric test for monotonicity. Internal Technical Information Document ST9725, Department of Statistics, Huntingdon Life Sciences, Huntingdon

    Google Scholar 

  • International Conference on Harmonization (2001) S7A – Safety pharmacology studies for human pharmaceuticals. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074959.pdf. Accessed 1 Sept 2014

  • International Conference on Harmonization (2005) S5(R2) – detection of toxicity to reproduction for medicinal products & toxicity to male fertility. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf. Accessed 1 Oct 2014

  • International Conference on Harmonization (2010) M3(R2) – nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 30 June 2014

  • Jonckheere AR (1954) A distribution-free k-sample test against ordered alternatives. Biometrika 41:133–145

    Article  MATH  MathSciNet  Google Scholar 

  • Lachin J (2011) Power and sample size evaluation for the Cochran–Mantel–Haenszel mean score (Wilcoxon rank sum) test and the Cochran–Armitage test for trend. Stat Med 30:3057–3066

    Article  MathSciNet  Google Scholar 

  • Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22

    Article  MATH  MathSciNet  Google Scholar 

  • McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1138

    Google Scholar 

  • McCarthy JC (1967) Effects of litter size and maternal weight on foetal and placental weight in mice. J Reprod Fertil 14:507–510

    Article  Google Scholar 

  • Palmer AK (1974) Statistical sampling and choice of sampling units. Teratology 10:301–302

    Article  Google Scholar 

  • Rochon J (1991) Sample size calculation for two-group repeated-measures experiments. Biometrics 47:1383–1398

    Google Scholar 

  • Ryan L (1992) Quantitative risk assessment for developmental toxicity. Biometrics 48:163–174

    Article  Google Scholar 

  • Selwyn MR (1988) Preclinical safety development. In: Peace KE (ed) Biopharmaceutical statistics for drug development. Marcel Dekker, New York, pp 231–271

    Google Scholar 

  • Shirley E (1977) A nonparametric equivalent of Williams’ test for contrasting existing dose levels of a treatment. Biometrics 33:386–389

    Article  MATH  Google Scholar 

  • Senn S (2007) Statistical issues in drug development. Wiley, Chichester, pp 99–100

    Google Scholar 

  • Sivarajah A1, Collins S, Sutton MR, Regan N, West H, Holbrook M, Edmunds N (2010) Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power. J Pharmacol Toxicol Methods 62(1):12–19

    Google Scholar 

  • Sparrow S, Robinson S, Bolan S, Bruce C, Danks A, Everett D, Fulcher S, Hill RE, Palmer H, Scott EW, Chapman KL (2011) Opportunities to minimize animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regul Toxicol Pharmacol 61:222–229

    Article  Google Scholar 

  • Staples RE, Haseman JK (1974) Selection of appropriate experimental units in teratology. Teratology 9:259–260

    Article  Google Scholar 

  • Tukey JW, Ciminera JL, Heyse JF (1985) Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41(1):295–301

    Article  MATH  Google Scholar 

  • U.S. Food and Drug Administration (2006) Guidance for industry – nonclinical safety evaluation of pediatric drug products. U.S. Food and Drug Administration, Rockville

    Google Scholar 

  • Weaver J, Brunden M (1998a) Design of developmental and reproductive toxicity studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 291–308

    Google Scholar 

  • Weaver J, Brunden M (1998b) The design of long term carcinogenicity studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 227–258

    Google Scholar 

  • Williams DA (1971) A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27:103–117

    Article  Google Scholar 

  • Williams DA (1972) The comparison of several dose levels with a zero dose control. Biometrics 28:519–531

    Article  Google Scholar 

  • Williams DA (1975) The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31:949–952

    Article  MATH  Google Scholar 

  • Zeger SL, Liang KY (1986) Longitudinal data for discrete and continuous outcomes. Biometrics 42:121–130

    Article  Google Scholar 

  • Zoetis T, Walls I (eds) (2003) Principles and practices for direct dosing of pre-weaning mammals in toxicity testing and research. A report of the ILSI risk science institute expert working group. ILSI, Washington DC

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David M. Potter .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bailey, S.A., Li, D., Potter, D.M. (2016). General Toxicology, Safety Pharmacology, Reproductive Toxicology, and Juvenile Toxicology Studies. In: Zhang, L. (eds) Nonclinical Statistics for Pharmaceutical and Biotechnology Industries. Statistics for Biology and Health. Springer, Cham. https://doi.org/10.1007/978-3-319-23558-5_10

Download citation

Publish with us

Policies and ethics